In this book, the authors present current research in the study of non-small cell lung cancer. Topics discussed include the preclinical and clinical advances of epigenetics in lung cancer; therapeutic antibodies and non-coding RNAs (ncRNAs) in non-small cell lung cancer; molecular profiling in lung cancer specimens leads to targeted therapeutic options in patients with non-small cell lung carcinoma; the role of radiation dose escalation in the treatment of stage III locally advanced inoperable non-small cell lung cancer; and mechanisms of resistance to EGFR inhibitors.